154 related articles for article (PubMed ID: 30214315)
1. Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients.
Weberpals J; Jansen L; Silversmit G; Verbeeck J; van der Geest L; Vissers PA; Zadnik V; Brenner H
Clin Epidemiol; 2018; 10():1109-1125. PubMed ID: 30214315
[TBL] [Abstract][Full Text] [Related]
2. Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators.
Mi X; Hammill BG; Curtis LH; Greiner MA; Setoguchi S
J Clin Epidemiol; 2013 Aug; 66(8 Suppl):S138-44. PubMed ID: 23849148
[TBL] [Abstract][Full Text] [Related]
3. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study.
Mi X; Hammill BG; Curtis LH; Lai EC; Setoguchi S
Stat Med; 2016 Nov; 35(26):4824-4836. PubMed ID: 27350312
[TBL] [Abstract][Full Text] [Related]
4. Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis.
Weberpals J; Jansen L; van Herk-Sukel MPP; Kuiper JG; Aarts MJ; Vissers PAJ; Brenner H
Eur J Epidemiol; 2017 Nov; 32(11):1019-1031. PubMed ID: 28864947
[TBL] [Abstract][Full Text] [Related]
5. A modified landmark method for dealing with an event observed during a follow-up period.
Hamajima N; Ohyashiki K; Toyama K
Jpn J Clin Oncol; 1995 Apr; 25(2):51-4. PubMed ID: 7745823
[TBL] [Abstract][Full Text] [Related]
6. Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database.
Agarwal P; Moshier E; Ru M; Ohri N; Ennis R; Rosenzweig K; Mazumdar M
Cancer Control; 2018; 25(1):1073274818789355. PubMed ID: 30021466
[TBL] [Abstract][Full Text] [Related]
7. An unjustified benefit: immortal time bias in the analysis of time-dependent events.
Gleiss A; Oberbauer R; Heinze G
Transpl Int; 2018 Feb; 31(2):125-130. PubMed ID: 29024071
[TBL] [Abstract][Full Text] [Related]
8. The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example.
Duchesneau ED; Jackson BE; Webster-Clark M; Lund JL; Reeder-Hayes KE; Nápoles AM; Strassle PD
Cancer Epidemiol Biomarkers Prev; 2022 Nov; 31(11):2079-2086. PubMed ID: 35984990
[TBL] [Abstract][Full Text] [Related]
9. Analysis of sequential treatment protocols for endometriosis-associated infertility.
Olive DL; Lee KL
Am J Obstet Gynecol; 1986 Mar; 154(3):613-9. PubMed ID: 3953706
[TBL] [Abstract][Full Text] [Related]
10. Metformin and pancreatic cancer survival: Real effect or immortal time bias?
Wei M; Liu Y; Bi Y; Zhang ZJ
Int J Cancer; 2019 Oct; 145(7):1822-1828. PubMed ID: 30848544
[TBL] [Abstract][Full Text] [Related]
11. Medications and the Risk of Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Use of the Landmark Method.
Choi YY; Lee JK; Kim HS; Kim DW; Kim HM; Kang DR
Yonsei Med J; 2021 Nov; 62(11):997-1004. PubMed ID: 34672133
[TBL] [Abstract][Full Text] [Related]
12. Immortal time bias in observational studies of time-to-event outcomes.
Jones M; Fowler R
J Crit Care; 2016 Dec; 36():195-199. PubMed ID: 27546771
[TBL] [Abstract][Full Text] [Related]
13. Immortal Time Bias in National Cancer Database Studies.
Newman NB; Brett CL; Kluwe CA; Patel CG; Attia A; Osmundson EC; Kachnic LA
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):5-12. PubMed ID: 31404580
[TBL] [Abstract][Full Text] [Related]
14. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study.
Cho IS; Chae YR; Kim JH; Yoo HR; Jang SY; Kim GR; Nam CM
BMC Med Res Methodol; 2017 Aug; 17(1):126. PubMed ID: 28830373
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.
Karim ME; Gustafson P; Petkau J; Tremlett H;
Am J Epidemiol; 2016 Aug; 184(4):325-35. PubMed ID: 27455963
[TBL] [Abstract][Full Text] [Related]
16. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.
Daniel S; Koren G; Lunenfeld E; Levy A
Am J Obstet Gynecol; 2015 Mar; 212(3):307.e1-6. PubMed ID: 25265406
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.
Huang L; Balavarca Y; van der Geest L; Lemmens V; Van Eycken L; De Schutter H; Johannesen TB; Zadnik V; Primic-Žakelj M; Mägi M; Grützmann R; Besselink MG; Schrotz-King P; Brenner H; Jansen L
BMC Med; 2019 Mar; 17(1):66. PubMed ID: 30905320
[TBL] [Abstract][Full Text] [Related]
18. Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database.
Herskovic A; Mauer E; Christos P; Nagar H
J Thorac Oncol; 2017 Feb; 12(2):302-313. PubMed ID: 27746190
[TBL] [Abstract][Full Text] [Related]
19. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.
Memon K; Kulik L; Lewandowski RJ; Wang E; Riaz A; Ryu RK; Sato KT; Marshall K; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Senthilnathan S; Baker T; Gates VL; Abecassis M; Benson AB; Mulcahy MF; Omary RA; Salem R
Gastroenterology; 2011 Aug; 141(2):526-35, 535.e1-2. PubMed ID: 21664356
[TBL] [Abstract][Full Text] [Related]
20. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy.
Park HS; Gross CP; Makarov DV; Yu JB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1365-73. PubMed ID: 22342097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
